Objective: The aim of this study was to evaluate the incidence, risk factors, and effect on outcomes of right ventricular failure in a large population of patients implanted with continuous-flow left ventricular assist devices.
An estimated 200,000 Americans over the age of 45 years have advanced heart failure for which medical therapy is insufficient. 1 Although cardiac transplantation remains an attractive therapeutic option for select patients, only 2000 heart transplantations are performed each year in the United States, largely as a result of donor shortages. 2 This continued limitation underscores the need for alternative avenues of treatment for this patient cohort.
Mechanical circulatory support, and more specifically left ventricular assist devices (LVADs), can be used in this setting as a bridge to transplantation (BTT), as destination therapy for patients who are not suitable for transplantation, and as temporary support for patients whose cardiac function is expected to recover. However, outcomes of patients are critically dependent on right ventricular (RV) function, which must provide sufficient flow through the pulmonary vasculature to fill the LVAD and ensure optimal performance. The physiology of right ventricular failure (RVF) in patients with LVADs has been evaluated previously, and the role of septal position and movement secondary to LVAD assistance was demonstrated as a potential mechanism for RVF, which is counterbalanced by significant reductions in RV afterload and pulmonary pressures. 3, 4 However, these mechanisms were derived mostly from the study of pulsatile LVADs, and there is a question about whether these precepts are still applicable for continuous-flow pumps.
The development of RVF in patients with an LVAD has a direct effect on mortality and is associated with prolonged length of intensive care unit and hospital stay. [5] [6] [7] [8] [9] [10] Patients with severe RVF requiring biventricular assist devices (BiVADs) have been shown to be more severely ill, with significantly higher preoperative creatinine levels, total bilirubin levels, and need for intra-aortic balloon pump (IABP) support than patients who were adequately supported with isolated LVADs. 11 Furthermore, RVF in patients with LVADs leads to increased morbidity, including end-organ dysfunction, 8, 11 which can deteriorate further after LVAD implantation, resulting in poor outcomes after cardiac transplantation. 12 With proper identification of patients at high risk for RVF, planned use of paracorporeal BiVADs might be appropriate in such patients. 13, 14 Temporary right ventricular assist devices (RVADs) can also be used in conjunction with chronic LVADs for patients who are identified as only needing a few days or weeks of RV support. Consequently, recent studies have attempted to ascertain univariate, 8, 15 as well as multivariate, 16 predictors of RVF to identify patients at risk for RVF after LVAD implantation. Preoperative identification of such patients might help in pre-emptive placement of RVADs, which could improve overall VAD outcomes. 13 Most of the current studies describing RVF in patients with LVADs are either limited by a small sample size or a single-center experience or were done on earlier-generation pulsatile devices. 8, 9, 15, 17 The incidence of the need for RVADs and extended inotropic support have been published for the initial HeartMate II (Thoratec, Pleasanton, Calif) trial results. 18, 19 However, a detailed analysis of multicenter data for the risks of RVF with the continuous-flow devices has not been established for a large group of patients. The aim of this study was to evaluate the incidence, risk factors, and effect on outcomes of RVF in patients implanted with the HeartMate II continuous-flow LVAD.
MATERIALS AND METHODS Study Design
Data were analyzed from the multicenter HeartMate II pivotal clinical trial for BTT. Details of the study design and trial results have been previously published for the initial 133 patients, 18 and updated results have been published for 281 patients. 19 Between March 2005 and April 2008, the total enrollment reached 484 patients at 36 centers, and these patients were included in this analysis. Patients listed as status 1A or 1B on the heart transplant list were implanted with the HeartMate II LVAD, and survival to transplantation, actuarial survival, functional status, quality of life, and adverse events were determined. All adverse events, including RVF, were adjudicated by an independent clinical events committee.
RVF was defined in the HeartMate II clinical trial as either the need for an RVAD in addition to the LVAD (group 1), continuous inotropic support for at least 14 days after implantation (group 2), or late inotropic support starting 14 days after implantation (group 3). Data from groups 1 and 2 were combined to form an early RVF group, whereas group 3 patients were examined separately (late RVF group). The rationale for differentiating early and late occurrences of RVF is that the cause of the RVF is likely triggered by different mechanisms. Baseline preoperative demographic, clinical, hemodynamic, and laboratory data were compared between patients with early RVF (groups 1 and 2) and patients without RVF to identify potential predisposing risk factors. The effect of RVF on survival to transplantation, recovery, or continuing support at 180 days after implantation and on Kaplan-Meier actuarial survival was also determined.
Data analyzed included patients' characteristics and demographics (age, sex, cause of heart failure, and body surface area), baseline hemodynamics (cardiac index, pulmonary capillary wedge pressure [PCWP] , mean pulmonary artery pressure, systolic pulmonary artery pressure, diastolic pulmonary artery pressure, central venous pressure [CVP] , CVP/PCWP ratio, 20 right ventricular stroke work index [RVSWI] , systolic blood pressure, left ventricular ejection fraction, and left ventricular end-diastolic volume), use of an IABP or ventilator support, laboratory data (blood urea nitrogen [BUN] , creatinine, alanine aminotransferase, total bilirubin, hematocrit, white blood cell count [WBC], platelet count, and international normalized ratio), and postoperative bleeding and transfusion requirements. The University of Michigan RVF risk score (MRVFRS) was calculated based on the formula provided by Matthews and colleagues. 16 
Statistical Analysis
Differences between measures of continuous variables with and without RVF were analyzed by using the independent-samples t test for normal data and the Mann-Whitney U test for nonnormal data. of a P value of less than .1. Survival analysis for patients continuing on mechanical support was performed with the Kaplan-Meier method. Differences in actuarial survival were evaluated by using the log-rank test. Patients were censored for transplantation, recovery of the native heart, and withdrawal from the study. All continuous parameters were first dichotomized at the 25th, 33rd, 50th, 66th, and 75th percentiles, and the percentile value with the lowest P value was chosen as the threshold for the analysis. The dichotomization took place at the 25th (BSA and hematocrit), 50th (mean pulmonary artery pressure and systolic pulmonary artery pressure), 66th (CVP), and 75th (CVP/PCWP, creatinine, BUN, AST, and WBC) percentiles. For RVSWI, the threshold was set at 300 mm Hg$ mL $ m
À2
, which has previously been shown to be a critical value for RVAD implantation. 21 The MRVFRS was dichotomized based on the critical value previously proposed by Matthews and colleagues. 16 Biochemical and hemodynamic variables are presented as means AE standard deviations, and categoric variables are presented as percentages. All statistical analyses were done with SYSTAT (Cranes Software, Chicago, Ill).
RESULTS

Baseline Characteristics and RVF Incidence
Baseline data and comparisons between groups are summarized in Table 1 . A total of 98 (20%) of the 484 patients had some form of RVF according to trial definitions. This included 30 (6%) patients requiring an RVAD (group 1), 35 (7%) patients requiring at least 14 days of continuous inotropic support after implantation (group 2), and 33 (7%) patients requiring late inotropic support starting after the 14th day (group 3). Demographic and hemodynamic data were typical of patients with advanced heart failure and were similar between patients with early RVF and patients without RVF, with the following notable exceptions: baseline CVP was significantly higher in patients with early RVF (15.0 AE 7.0 mm Hg), especially for patients requiring RVADs (16.1 AE 6.4 mm Hg), when compared with those without RVF (12.3 AE 6.4 mm Hg, P ¼ .002). Similarly, the CVP/ PCWP ratio was significantly higher for the early RVF groups compared with the no-RVF group (0.60 AE 0.20 vs 0.51 AE 0.46), and mean RVSWI was significantly lower for the early RVF group (477 AE 306 vs 556 AE 298 mm Hg$mL
Furthermore, more than 30% of A significantly higher proportion of the few patients (n ¼ 40) on ventilator support before HeartMate II implantation had early RVF compared with those who were not (40% vs 11%, P < .001), 28% of whom required an RVAD. Finally, the AST value was significantly higher in those requiring an RVAD compared with that seen in those who did not have RVF (236 AE 557 v 74 AE 201 mg/dL, P<.03). Patients with early RVF had a higher MRVFRS (1.65 AE 2.00 vs 1.14 AE 1.88, P<.02), whereas there was no significant difference between the corresponding RVF subgroups.
Of the patients who were started on an RVAD, 14 received a Centrimag (Levitronix, Waltham, Mass), 9 received an Abiomed (Abiomed, Danvers, Mass), 3 received a Tandem Heart (Cardiac Assist, Pittsburgh, Pa), and 4 received a Thoratec paracorporeal VAD (Thoratec, Pleasanton, Calif) ( Table 2 ). Most RVADs were implanted within the first 24 hours of LVAD surgery. Eight patients received an RVAD after 24 hours, with 1 patient receiving an RVAD 38 days after LVAD surgery. Three of these 8 patients underwent transplantation, 4 died, and 1 was withdrawn. Durations of support for all RVADs ranged from 0 to 408 days.
Clinical Outcome
In patients without RVF, 342 (89%) survived to transplantation, recovery, or continuing support at 180 days (Table 3) . Patients with early RVF had significantly worse survival to the same end points (n ¼ 46, 71%; P ¼ .001), with those requiring RVADs having the lowest percentage reaching these outcomes (n ¼ 20, 67%; P < .001). Within the RVAD group, 17 (77%) of 22 patients who received an RVAD within the first 24 hours survived to the primary outcome at 180 days, whereas only 3 (39%) of 8 patients who received an RVAD later survived to the same end point. Actuarial survival at 1 year was also significantly better for patients without RVF (79%) compared with that in patients requiring RVADs (group 1, 59%; P ¼ .004) or extended inotropes (group 2, 56%; P ¼ .007), whereas there was no difference for patients with late inotrope use (group 3, 75%; P ¼ .81). Decreased survival for patients with early RVF is evident in the grouped Kaplan-Meier survival curve (Figure 1) .
Hospital length of stay for discharged patients was longer for those requiring an RVAD than for those without RVF (32 vs 22 days, P<.001). Those who required inotropic support for more than 14 days after LVAD implantation and those with late inotropic support had an average length of stay of 35 and 32 days, respectively. Thus any RVF resulted in a significantly longer hospitalization time before discharge than seen in those without any RVF (P < .001).
Univariate and Multivariate Preoperative Risk Factors
Univariate analyses of predictors of RVF are shown in Table 4, and the associated relative risk ratios are depicted in Figure 2 . The hemodynamic variables of CVP greater than 15 mm Hg, RVSWI less than 300 mm Hg$mL$m À2 , and a CVP/PCWP ratio greater than 0.63 were statistically significant predictors that indicated a higher risk of RVF. There were no statistically significant differences in pulmonary artery pressures or pulmonary vascular resistance between groups. With a baseline CVP of greater than 15 mm Hg, 19% of patients had early RVF compared with 10% of patients with a CVP of less than 15 mm Hg (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.2-3.6; P < .01). Similarly 22% of patients with a CVP/PCWP ratio of greater than 0.63 had early RVF compared with 11% with a CVP/ PCWP ratio of less than 0.63, and 26% of patients with an RVSWI of less than 300 mm Hg$mL$m À2 had RVF compared with 10% of patients with an RVSWI of greater than 300 mm Hg$mL$m À2 . Increased WBC and lower hematocrit values were also statistically significant between those who required RVAD support and those who did not. Patients on preoperative ventilator support were 5 times more likely to have RVF compared with those without ventilator support. were the significant independent preoperative predictors of early RVF after LVAD implantation. The area under the receiver operating curve was 0.68, which is comparable with that seen in earlier risk models of RVF. 16 
Intraoperative and Postoperative Factors
There were no significant differences in bleeding and transfusion requirements during implantation or within the first 48 hours of LVAD implantation (Table 5) for those who eventually had RVF. However, patients implanted with an RVAD required a greater number of units of packed red blood cell transfusions compared with those without RVF (14.3 AE 18.9 vs 5.6 AE 5.8 units, P<.03) and more often required a reoperation for bleeding (40% vs 19%, P < .04). Fifty-three percent of patients who needed an RVAD required greater than 6 units of packed red blood cells during the implantation procedure, whereas only 26% of those without RVF required similar levels of transfusion. Cardiopulmonary bypass times were higher in those who required an RVAD (149 AE 76 vs 106 AE 61 minutes, P<.005), which is likely attributable to the additional surgical procedures required to implant an RVAD.
DISCUSSION
Patients receiving the HeartMate II continuous-flow LVAD as a BTT demonstrated a 6% incidence of RVF requiring an RVAD and a 7% incidence of extended inotropic support, for an overall incidence of early RVF of 13%. Patients receiving the HeartMate II with early RVF had a 20% reduction in 1-year survival compared with that seen in patients who did not have RVF. In addition, patients requiring inotropic agents starting 14 days after LVAD implantation did not have a reduction in survival, although their length of hospital stay was increased. The overall incidence of early RVF seems to have decreased from those reported previously, 8, 9, 11 which can be attributed to the improved patient selection and optimization of the right heart before LVAD implantation. The presence of RVF of any sort was associated with longer cardiopulmonary bypass times during surgical intervention and the subsequent need for blood transfusions, with the highest values in patients requiring an RVAD. RVSWI, increased preimplantation CVP, increased preimplantation CVP/PCWP ratio, and impaired renal or respiratory function also appear to predispose to the need for an RVAD after LVAD implantation.
Several previous studies have attempted to understand the mechanism leading to RVF in LVAD recipients, and numerous conflicting reports contest to the complex host of variables at play in this setting. One of the more common explanations is that the acute unloading of the left heart ventricle leads to a septal shift that alters RV shape and size, thereby affecting its contractility. 3, 4, 22 In addition, pre-existing RV impairment might be unmasked with the increase in right-sided preload afforded by LVAD perfusion. 4, 8 These aspects are now being routinely considered at the time of LVAD and when deciding on device settings to keep the septal shift to a minimum.
There is a common misconception that the reduced survival rate in patients requiring biventricular support is due RVF, Right ventricular failure; RVAD, right ventricular assist device. *P < .05, yP < .01, and zP < .001 compared with the no-RVF group. FIGURE 1. Kaplan-Meier survival for patients with and without early RVF receiving the HeartMate II LVAD, which includes the need for RVADs or extended inotropic support for more than 14 days.
to the BiVADs themselves. However, there is ample evidence that the same preoperative risk factors that predispose a patient to RVF are also risk factors for mortality after LVAD support. In more recent studies, laboratory variables associated with pre-LVAD severity of illness, which are indirectly related to RV function (eg, bilirubin, creatinine, ventilatory support, and IABP use) were found to be more strongly associated with the need for biventricular support as opposed to preimplantation hemodynamic variables. 11, 16, 23 These variables might be influencing the predisposition to perioperative bleeding, which negatively affects pulmonary flow because of the interstitial edema associated with blood transfusion and lung damage. In another analysis of 245 patients, the need for pre-LVAD circulatory support, female sex, and nonischemic cause were found to independently predict RVF after LVAD placement. 9 A more recent study evaluating preoperative RV geometry and tricuspid incompetence found these factors to reliably predict RVF in LVAD recipients. 24 However, limitations, such as small sample sizes, single-center nature, and pump type, have precluded these findings from being applicable to patients implanted with newer continuous-flow devices.
This report is the largest to date analyzing the effect of continuous-flow LVADs on RV function. The primary finding was that a combination of hemodynamic and clinical variables can be used to identify patients who might be at high risk for RVF. A high preoperative WBC, BUN value, and preoperative ventilatory support, along with increased CVP, CVP/PCWP ratio, and decreased RVSWI, were found to be significant univariate predictors of RVF. High CVP and low RVSWI before LVAD implantation can be associated with 2 conditions: worsening right heart function as a result of increased left-sided filling pressures and thus pulmonary hypertension (group A) and intrinsic right heart dysfunction as a result of a progressive myopathic process (group B). The CVP/PCWP ratio was used to better differentiate between patients who fall in group A from those in group B. Hence those with right-sided dysfunction as a result of persistently high left-sided filling pressure would have a low CVP/PCWP ratio, and those with intrinsic RV dysfunction would have a high CVP/PCWP ratio. A CVP/ PCWP ratio of greater than 0.63, which represents the 75th percentile of values in the overall population, was in fact an independent multivariate risk factor for RVF, and notably, CVP was not. Thus patients with a CVP that approaches the left-sided filling pressure before LVAD might represent the group at highest risk for right heart failure after LVAD implantation. In addition, those who have a lack of RV contractile reserve and have a relatively greater increase of right-sided filling pressures might have more septal shift and increased venous return, which outweighs any benefits of left ventricular unloading. Identifying such risk factors is clinically relevant because it might help in selecting patients who will benefit from biventricular rather than univentricular support. This is especially important because recent studies have shown that a planned placement of biventricular support results in superior outcomes compared with delayed conversion of LVADs to biventricular support. 13 Preoperative optimization strategies can also help the right ventricle, for example by reducing the volume status as much as possible before the LVAD implantation. Although the incidence of RVAD insertion in LVAD recipients has been decreasing as clinical experience with RVF management accumulates, the mortality associated with RVF remains high. [5] [6] [7] 25 Moreover, this increased mortality is a direct result of RVF leading to less flow to the LVAD and therefore less pump output and increased venous pressure leading to decreased perfusion to vital organs. The findings of the current study were similar to those of these prior studies in that patients with RVF experienced a lower survival rate to transplantation, recovery, or continuing support at 180 days. These observations again reiterate the need for better selection of patients at high risk for RVF, which might help in preventing its occurrence by providing mechanical assistance to the right side simultaneously with LVAD implantation, as evidenced by improved 180-day survival in patients who received an RVAD within 24 hours of LVAD surgery.
Limitations of this study include its retrospective nature because of which there was no concurrent control group for comparison with pulsatile devices. Results from a randomized comparison of pulsatile and continuous-flow devices will be available at the conclusion of the HeartMate II Destination Therapy clinical trial. Although RVF was comprised of 3 groups, the early inotrope (group 2) and RVAD (group 1) groups exhibited similar survival characteristics, whereas the late inotrope group (group 3) resembled the no-RVF group. For this reason, the late inotrope group (group 3) was excluded from the RVF group for most of the analyses but should be the focus of future studies.
In conclusion, rates of RVF and RVAD requirement in patients with the HeartMate II are low relative to previous results with pulsatile LVADs and support the use of this device in those with end-stage heart failure. Nevertheless, the development of RVF remains difficult to predict, although our data suggest that both clinical and hemodynamic factors affect the development of RVF. RVF in HeartMate II recipients is associated with worse clinical outcomes than in patients without RVF, which underscores the importance of appropriate RVF management and prevention in this patient cohort.
